Announcements Trials
Browse Landscape

Status

No longer available 1

Sponsor Class

OTHER 1

Study Type

Interventional 4Expanded_access 1

Sponsor

Cancer Type

Dermatologic 3Genitourinary 1

Conditions

Progressive Metastatic Castrate Resistant Prostate Cancer 1

Interventions

gallium 68 PSMA-11 4Magnetic Resonance Spectroscopy 4Abiraterone Acetate 3carbon-11 acetate 2Prednisone 2Prednisolone 2Axitinib 22-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 2zenocutuzumab 1ulixertinib 1trametinib 1tempol 1tazemetostat 1talazoparib 1radium Ra 223 dichloride 1pegilodecakin 1omburtamab I-131 1niraparib 1neratinib 1motexafin gadolinium 1enfortumab vedotin 1dodecyl maltoside 1bicalutamide 1bemarituzumab 1balstilimab 1atezolizumab 1apalutamide 1TEMPOL-H 1Suspensions 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × trametinib × Genitourinary × Clear all
NCT03386071 2019-01-16

Compassionate Use: Progressive Metastatic Castrate Resistant Prostate Cancer; Monotherapy Treatment With Trametinib

Jonsson Comprehensive Cancer Center

No longer available
Genitourinary

Progressive Metastatic Castrate Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡